COMPANY

Phoenix Nest

HQ: Brooklyn, NY source · phoenixnestbiotech.com ↗ · Mid-Atlantic

Location: Brooklyn, NY · source · Oct 14, 2026

Profile checked Oct 10, 2026

16NIH grants

Funding and NIH signals

NIH award NIH awarded $1.49M (SBIR Phase II 1R44NS147802-01, new, notice Jul 14, 2026). NIH RePORTER 1R44NS147802-01 (Jul 14, 2026)
Evidence (1 event)
- Jul 14, 2026 · NIH RePORTER 1R44NS147802-01
  Organization: PHOENIX NEST, INC.; City/State: BROOKLYN, NY; Project number: 1R44NS147802-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 1492329; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Manufacturing and Analytical Development for JLK-247 Gene Therapy; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jul 14, 2026 Grant Government grant — SBIR: $1.49M (annual award, as published), announced Jul 14, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Aug 14, 2025 Grant Government grant — SBIR: $1.06M (annual award, as published), announced Aug 14, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

Funding

Last 2 years.

Jul 14, 2026 Government grant — SBIR: $1.49M (annual award, as published), announced Jul 14, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Aug 14, 2025 Government grant — SBIR: $1.06M (annual award, as published), announced Aug 14, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

NIH awards 16

Annual award amounts. Total $15.2M.

Jul 1, 2024 NIH award 1R44NS137892-01 FY2024: $881,675 awarded for that fiscal year; activity R44 (SBIR); PI SINGAMSETTY, SRIKANTH; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Identification of Potential Biomarkers a source ↗
Mar 28, 2024 NIH award 3UB1NS122644-04S1 FY2024: $100,000 awarded for that fiscal year; activity UB1 (OTHER_NIH); PI SINGAMSETTY, SRIKANTH; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Evaluation of Clinical Outcome As source ↗
Mar 21, 2024 NIH award 5UB1NS122644-04 FY2024: $798,341 awarded for that fiscal year; activity UB1 (OTHER_NIH); PI SINGAMSETTY, SRIKANTH; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Evaluation of Clinical Outcome Asse source ↗
Sep 12, 2023 NIH award 5R44NS129393-02 FY2023: $1,494,895 awarded for that fiscal year; activity R44 (SBIR); PI SINGAMSETTY, SRIKANTH; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Development of Gene Replacement Therap source ↗
Apr 21, 2023 NIH award 5UB1NS122644-03 FY2023: $1,125,625 awarded for that fiscal year; activity UB1 (OTHER_NIH); PI SINGAMSETTY, SRIKANTH; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Evaluation of Clinical Outcome As source ↗
Sep 19, 2022 NIH award 1R44NS129393-01 FY2022: $1,495,610 awarded for that fiscal year; activity R44 (SBIR); PI SINGAMSETTY, SRIKANTH; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Development of gene replacement therap source ↗
Mar 30, 2022 NIH award 5UB1NS122644-02 FY2022: $1,125,627 awarded for that fiscal year; activity UB1 (OTHER_NIH); PI SINGAMSETTY, SRIKANTH; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Evaluation of clinical outcome as source ↗
Jan 9, 2022 NIH award 5U44NS089061-05 FY2022: $2,435,870 awarded for that fiscal year; activity U44 (SBIR); PI WOOD, JILL; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Development and Validation of Therapy for Mucopol source ↗
Sep 21, 2021 NIH award 1UB1NS122644-01A1 FY2021: $370,341 awarded for that fiscal year; activity UB1 (OTHER_NIH); PI SINGAMSETTY, SRIKANTH; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Evaluation of clinical outcome as source ↗
Sep 24, 2018 NIH award 2U44NS089061-04 FY2018: $3,176,406 awarded for that fiscal year; activity U44 (SBIR); PI WOOD, JILL; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Development and validation of therapy for mucopol source ↗
Sep 13, 2017 NIH award 1R41HD092110-01 FY2017: $224,873 awarded for that fiscal year; activity R41 (STTR); PI SINGAMSETTY, SRIKANTH; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Structure-based optimization of a novel source ↗
Apr 6, 2017 NIH award 5R42NS089061-03 FY2017: $777,801 awarded for that fiscal year; activity R42 (STTR); PI EKINS, SEAN; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Development and validation of therapy for mucopoly source ↗
May 21, 2016 NIH award 2R42NS089061-02 FY2016: $717,207 awarded for that fiscal year; activity R42 (STTR); PI EKINS, SEAN; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Development and validation of therapy for mucopoly source ↗
Feb 9, 2016 NIH award 1R41NS092221-01A1 FY2016: $224,469 awarded for that fiscal year; activity R41 (STTR); PI EKINS, SEAN; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Engineering stem cells to make mucopolysaccharid source ↗
Mar 11, 2015 NIH award 3R41NS089061-01S1 FY2015: $1,500 awarded for that fiscal year; activity R41 (STTR); PI EKINS, SEAN; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Development and in vitro validation of therapy for source ↗
Aug 25, 2014 NIH award 1R41NS089061-01 FY2014: $223,102 awarded for that fiscal year; activity R41 (STTR); PI EKINS, SEAN; recipient as written: PHOENIX NEST, INC., BROOKLYN, NY. Development and in vitro validation of therapy for source ↗